Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecallantide for ACE Inhibitor Induced Angioedema
NCT01343823Phase 2Terminated
- Sponsor
- Takeda
- Start
- Jun 2011
- Primary completion
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ecallantide (4 arms), sponsored by Takeda. Primary endpoints: Safety and Efficacy of Ecallantide (Discharge Eligibility) at 6 hours and Safety (Adverse Events) at 6 hours. Started Jun 2011; status: terminated.
02
Drugs
ecallantide
Beyond the preview
Go deeper on NCT01343823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01343823.